TaiMed Biologics was featured in an interview with PharmaBoardroom, sharing how its CD4-targeted platform has expanded into the fields of autoimmune diseases and precision medicine through ADC technology.

In the conversation, Dr. Chang reflects on TaiMed Biologics’ evolution, from building a long-acting antibody platform to advancing HIV programs toward late-stage development, and how we think about scaling innovation through global development and strategic partnerships.TaiMed has validated its CD4-targeting antibody platform with a first-in-class long-acting dual-antibody HIV therapy and is advancing a next-generation, long-acting regimen that could redefine treatment adherence and patient outcomes. Building on this foundation, the company is now extending its technology into autoimmune diseases and antibody-drug conjugates (ADCs), positioning Taiwan as an emerging force in precision biologics.

The interview also explores how scientific rigor, clinical execution, and long-term vision come together as we work to deliver more durable, patient-centric HIV therapies.

For the full interview, please visit the PharmaBoardroom website.